Weissleder, Ralph http://orcid.org/0000-0003-0828-4143
Pittet, Mikael J. http://orcid.org/0000-0002-2060-4691
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (UH3 CA202637, R01 CA204019, P01 CA069246, U01 CA206890, R01 CA206997, R01 AI084880, R01 CA206890, R01 CA218579, P01 CA240239, U01 CA224348)
Samana Cay MGH Research Scholar Fund
Article History
Received: 29 August 2019
Accepted: 4 February 2020
First Online: 18 March 2020
Change Date: 6 April 2020
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41551-020-0554-5
Competing interests
: R.W. has received consultancy payments from ModeRNA, Tarveda Pharmaceuticals, Alivio Therapeutics and Accure Health, and is a shareholder of T2Biosystems, Lumicell and Accure Health. M.J.P. has received consultancy payments from Aileron Therapeutics, AstraZeneca, Elstar Therapeutics, KSQ Therapeutics, MPM Capital, Siamab Therapeutics, Third Rock Ventures and Tidal Therapeutics. All patents associated with R.W. and M.J.P. have been assigned to, and handled by, the Massachusetts General Hospital.